An Open-label, Pilot, Proof of Concept Study to Evaluate the Safety, Tolerability, and Efficacy of Oral Etrasimod (APD334) in Patients With Primary Biliary Cholangitis

Trial Profile

An Open-label, Pilot, Proof of Concept Study to Evaluate the Safety, Tolerability, and Efficacy of Oral Etrasimod (APD334) in Patients With Primary Biliary Cholangitis

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 22 May 2017

At a glance

  • Drugs Etrasimod (Primary)
  • Indications Primary biliary cirrhosis
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Arena Pharmaceuticals
  • Most Recent Events

    • 15 May 2017 Status changed from planning to not yet recruiting.
    • 22 Mar 2017 New trial record
    • 14 Mar 2017 According to an Arena Pharmaceuticals media release, the company intends to initiate this trial in 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top